Biomarkers and 3D models predicting response to immune checkpoint blockade in head and neck cancer (review)

• Verfasst von: Affolter, Annette [VerfasserIn]
• Verfasst von: Kern, Johann [VerfasserIn]
• Verfasst von: Bieback, Karen [VerfasserIn]
• Verfasst von: Scherl, Claudia [VerfasserIn]
• Verfasst von: Rotter, Nicole [VerfasserIn]
• Verfasst von: Lammert, Anne [VerfasserIn]
• Titel: Biomarkers and 3D models predicting response to immune checkpoint blockade in head and neck cancer (review)
• Verf.angabe: Annette Affolter, Johann Kern, Karen Bieback, Claudia Scherl, Nicole Rotter, Anne Lammert
• E-Jahr: 2022
• Jahr: June 1, 2022
• Umfang: 22 S.
• Fussnoten: Gesehen am 07.11.2023
• Titel Quelle: Enthalten in: International journal of oncology
• Ort Quelle: Athens : Spandidos Publ., 2001
• Jahr Quelle: 2022
• Band/Heft Quelle: 61(2022), 1, Artikel-ID 88, Seite 1-22
• ISSN Quelle: 1791-2423
• DOI: doi:10.3892/ijo.2022.5378
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1869520793

Abstract

Immunotherapy has evolved into a powerful tool in the fight against a number of types of cancer, including head and neck squamous cell carcinomas (HNSCC). Although checkpoint inhibition (CPI) has definitely enriched the treatment options for advanced stage HNSCC during the past decade, the percentage of patients responding to treatment is widely varying between 14‑32% in second‑line setting in recurrent or metastatic HNSCC with a sporadic durability. Clinical response and, consecutively, treatment success remain unpredictable in most of the cases. One potential factor is the expression of target molecules of the tumor allowing cancer cells to acquire therapy resistance mechanisms. Accordingly, analyzing and modeling the complexity of the tumor microenvironment (TME) is key to i) stratify subgroups of patients most likely to respond to CPI and ii) to define new combinatorial treatment regimens. Particularly in a heterogeneous disease such as HNSCC, thoroughly studying the interactions and crosstalking between tumor and TME cells is one of the biggest challenges. Sophisticated 3D models are therefore urgently needed to be able to validate such basic science hypotheses and to test novel immuno‑oncologic treatment regimens in consideration of the individual biology of each tumor. The present review will first summarize recent findings on immunotherapy, predictive biomarkers, the role of the TME and signaling cascades eliciting during CPI. Second, it will highlight the significance of current promising approaches to establish HNSCC 3D models for new immunotherapies. The results are encouraging and indicate that data obtained from patient‑specific tumors in a dish might be finally translated into personalized immuno‑oncology.